8-K: PDS Biotech Reaffirms Guidance for Phase 3 Clinical Trial of Versamune HPV in Head and Neck Cancer

PDS Biotechnology reaffirms its plan to initiate the VERSATILE-003 Phase 3 clinical trial for Versamune HPV plus pembrolizumab in first-line treatment of recurrent and/or metastatic HPV16-positive head and neck squamous cell cancer (HNSCC) in Q1 2025.

Summary

• PDS Biotechnology Corporation has reaffirmed its guidance to initiate the VERSATILE-003 Phase 3 clinical trial in the first quarter of 2025.
• The trial will evaluate Versamune HPV in combination with pembrolizumab for the first-line treatment of recurrent and/or metastatic (R/M) HPV16-positive head and neck squamous cell cancer (HNSCC).
• The company submitted an updated clinical protocol on November 15, 2024, and the FDA comment window has passed.
• PDS Biotech has received Fast Track designation from the FDA for the combination therapy in R/M HNSCC.
• A companion diagnostic will be used to confirm HPV16-positive status during patient screening for the VERSATILE-003 trial.
• HPV16-positive HNSCC is becoming the dominant type of HNSCC in the US and EU.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the reaffirmation of the clinical trial initiation timeline and the potential of the Versamune HPV therapy. However, the forward-looking statements include standard risk disclosures, which temper the overall sentiment.

Positives

• FDA alignment on the Phase 3 trial design for VERSATILE-003.
• FDA Fast Track designation for Versamune HPV and pembrolizumab combination.
• Use of a companion diagnostic to identify suitable patients for Versamune HPV treatment.
• Strong Phase 2 trial safety, response, and survival results warrant Phase 3 study.
• Versamune HPV is the most clinically advanced HPV16 targeted program.

Risks

• The forward-looking statements include risks related to protecting intellectual property rights.
• The company's anticipated capital requirements and dependence on additional financing to fund operations and complete development and commercialization of product candidates are risks.
• The timing and future success of clinical trials for Versamune HPV, PDS01ADC, and other Versamune-based product candidates are subject to uncertainty.
• The company's ability to continue as a going concern is a risk factor.

Future Outlook

PDS Biotech plans to initiate a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers and is developing Versamune HPV in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

Management Comments

• 'The integral elements for trial initiation are ready, including alignment with the FDA,' said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech.
• 'We look forward to initiating VERSATILE-003 this quarter and advancing the combination of Versamune HPV plus pembrolizumab to potentially provide improved outcomes for patients with HPV16-positive R/M HNSCC.'
• Kirk Shepard, M.D., PDS Biotechs Chief Medical Officer, stated that confirming HPV16 status with a potentially commercializable test is essential to effectively identifying the patients suitable to receive Versamune HPV.

Industry Context

The announcement highlights the growing focus on targeted therapies for HPV16-positive head and neck cancers, a subgroup with significant unmet medical needs. The use of a companion diagnostic aligns with the trend towards personalized medicine in oncology.

Comparison to Industry Standards

• The document references KEYTRUDA (pembrolizumab) and Xtandi, which are registered trademarks of Merck Sharp & Dohme LLC and Astellas Pharma Inc., respectively, indicating that these are established treatments in the oncology space.
• The VERSATILE-002 trial results are compared to the KEYNOTE-048 and LEAP-010 trials, which evaluated pembrolizumab-based therapies in HNSCC, to highlight the potential of Versamune HPV in improving outcomes.
• The document mentions that competing EGFR antibody approaches have reported weaker clinical responses in HPV-positive HNSCC compared to HPV-negative HNSCC, suggesting that Versamune HPV may offer a more targeted and effective approach for this specific patient population.

Stakeholder Impact

• Positive impact on patients with HPV16-positive HNSCC through potential new treatment options.
• Potential benefit to shareholders through advancement of the company's lead program.
• Positive impact on the medical community through the development of a companion diagnostic for HPV16-positive HNSCC.

Next Steps

• Initiation of the VERSATILE-003 Phase 3 clinical trial in Q1 2025.
• File IND for Versamune MUC1 in Q2 2025.
• Data readout from VERSATILE-002 in Q3 2025.
• Interim data readouts for PDS01ADC + HAIP therapy and PDS01ADC + Xtandi in Q1 2026.
• Complete V-003 patient recruitment in Q3 2026.

Key Dates

Keywords

VERSATILE-003, Versamune HPV, pembrolizumab, HNSCC, HPV16-positive, clinical trial, PDS Biotechnology, immunotherapy, FDA, cancer